CN1273137C - Compound prepn. contg. Brufen arginine codeine - Google Patents
Compound prepn. contg. Brufen arginine codeine Download PDFInfo
- Publication number
- CN1273137C CN1273137C CN 200410016416 CN200410016416A CN1273137C CN 1273137 C CN1273137 C CN 1273137C CN 200410016416 CN200410016416 CN 200410016416 CN 200410016416 A CN200410016416 A CN 200410016416A CN 1273137 C CN1273137 C CN 1273137C
- Authority
- CN
- China
- Prior art keywords
- codeine
- ibuprofen
- parts
- arginine
- ibuprofen arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a compound preparation of ibuprofen arginine codeine. The preparation contains ibuprofen arginine and codeine or pharmaceutically acceptable codeine salts, wherein the mass proportion of the ibuprofen arginine to the codeine or pharmaceutically acceptable codeine salts is from 1 to 80:1. The water solubility of ibuprofen is improved due to the combination of ibuprofen and arginine. On one hand, in vivo absorption rates are increased, and on the other hand, stimulation to the gastrointestinal tract is reduced. Moreover, the obtained compound preparation takes effect rapidly, and the medicinal effects of the compound preparation are stable and lasting.
Description
(1) technical field
The present invention relates to contain the compound preparation of acceptable salt composite on ibuprofen arginine and codeine or its medicine.
(2) background technology
Codeine or its pharmaceutically acceptable salt (for example codeine phosphate) are taken as the coughing centre that can directly suppress brain by those skilled in the art, have stronger antitussive effect.That also known ibuprofen (a kind of NSAID (non-steroidal anti-inflammatory drug)) has is analgesic, antiinflammatory, analgesic activity.So, not only contain ibuprofen but also contained codeine or the Orally administered composition of its pharmaceutically acceptable salt is applicable to violent dry cough and the irritable cough that a variety of causes causes, be applicable to violent dry cough especially with chest pain.Its analgesic activity can be used for moderate pain, as postoperative pain and the pain relieving of moderate cancer pain etc.
But the ibuprofen in the said composition is because water-soluble hardly, pharmacokinetic parameters T
Max(reaching the time of maximum plasma concentration) value is 1.5-2h, and the same with other oral NSAID (NSAID (non-steroidal anti-inflammatory drug)), onset is slower relatively, and gastrointestinal tract is had certain stimulation.And the codeine onset is very fast relatively, and its pharmaceutically acceptable salt (as codeine phosphate) is after oral, and general onset time was at 30～45 minutes.Be absorbed in 1 hour and peak.How to make each prescription in the drug regimen bring into play its effect simultaneously, as early as possible, becoming such medicine mainly needs the technological difficulties that solve.
(3) summary of the invention
The present invention promptly is in order to provide a kind of rapid-action, efficacy stability easily promptly to be contained the compound preparation that ibuprofen contains codeine or its pharmaceutically acceptable salt again by what patient accepted, and this compound preparation is the compound preparation of ibuprofen arginine and codeine or its pharmaceutically acceptable salt.
The present invention reaches the technical scheme that goal of the invention adopts to be:
It is 1～80: 1 ibuprofen arginine and codeine or the pharmaceutically acceptable salt of described codeine that a kind of Codeine Ibuprofen Arginine Compound Preparation, described preparation contain mass ratio.Ibuprofen has improved the water solublity of ibuprofen because of arginic combination, and absorption rate increases in the body on the one hand, and also having reduced on the other hand stimulates gastrointestinal.
Further, described preparation is 1～80: 1 ibuprofen arginine and codeine or its pharmaceutically acceptable salt by mass ratio, and pharmaceutical excipient or carrier are formed.
The pharmaceutically acceptable salt mass ratio preferred 5～50: 1 of described ibuprofen arginine and codeine or codeine, more preferably 20～40: 1.
The front pharmaceutically acceptable salt of said codeine is preferably used codeine phosphate, promptly is ibuprofen arginine and codeine phosphate.
Described Codeine Ibuprofen Arginine Compound Preparation can be made into one of following dosage forms:
1. 2. 3. 5. slow releasing capsule of slow releasing tablet of capsule of tablet.
The prescription and the quality proportioning of described ibuprofen arginine codeine compound tablet are:
240～600 parts of ibuprofen arginines
12.5 parts of codeine phosphates
37.5 parts of lactose
37.5 parts of starch
15 parts of microcrystalline Cellulose
25 parts of 2% polyvidone aqueous solutions
2.8 parts of Pulvis Talci
0.9 part of magnesium stearate
Described ibuprofen arginine codeine compound tablet can prepare as follows:
(1) former, adjuvant are crossed 80 mesh sieves respectively;
(2) get ibuprofen arginine and codeine phosphate recipe quantity and starch mixing, add lactose, microcrystalline Cellulose mixing again;
(3) add 2% polyvidone aqueous solution and make soft material, granulate, drying adds Pulvis Talci, magnesium stearate mix homogeneously, tabletting behind the granulate.
Codeine Ibuprofen Arginine Compound Preparation can be made capsule, the content prescription and the quality proportioning of described ibuprofen arginine codeine compound capsule are:
240～600 parts of ibuprofen arginines
12.5 parts of codeine phosphates
10 parts of low-substituted hydroxypropyl celluloses
5 parts of starch
5 parts of micropowder silica gels
Ibuprofen arginine codeine compound capsule can prepare as follows:
(1) gets ibuprofen arginine and 40 mesh sieves, mix homogeneously are crossed in codeine recipe quantity, low-substituted hydroxypropyl cellulose, starch, micropowder silica gel;
(2) step (1) gained granule is encapsulated.
Codeine Ibuprofen Arginine Compound Preparation also can be made into slow releasing preparation, and the compound sustained-released tablet of ibuprofen arginine codeine is made up of slow release label, release layer and dyed layer;
Described slow release label prescription and quality proportioning are:
240～600 parts of ibuprofen arginines
30 parts of lactose
60 parts of HPMC
20 parts of ethyl celluloses
8.2 parts of magnesium stearate
Described release layer prescription and quality proportioning are:
500 parts of ibuprofen arginines
12.5 parts of codeine phosphates
Described dyed layer is:
45 parts of Opadries (Opadry)
The compound sustained-released tablet of described ibuprofen arginine codeine can prepare as follows:
(1) by above-mentioned prescription, the ethanol with 75% is wetting agent, and slow releasing tablet core component ibuprofen arginine, lactose, HPMC, ethyl cellulose are made granule after according to the recipe quantity mix homogeneously, and the adding magnesium stearate is a lubricant, and tabletting obtains the slow release label;
(2) ibuprofen arginine, codeine phosphate and the 50% ethanol mix homogeneously by release layer prescription amount carries out coating to label in coating pan, makes plain sheet;
(3) with above plain sheet further with recipe quantity the Opadry coating, promptly get the compound sustained-released tablet of described ibuprofen arginine codeine.
When Codeine Ibuprofen Arginine Compound Preparation was made compound sustained release capsules, the content of described ibuprofen arginine codeine compound sustained release capsules was made up of fast release micropill and slow-release micro-pill;
Described fast release micropill prescription and quality proportioning are:
240～600 parts of ibuprofen arginines
12.5 parts of codeine phosphates
8 parts of 2% polyvidone aqueous solutions
100 parts of ethanol
65 parts of celphere
Described slow-release micro-pill prescription and quality proportioning are:
240～600 parts of ibuprofen arginines
12.5 parts of codeine phosphates
15 parts of 2% polyvidone aqueous solutions
150 parts of ethanol
180 parts of celphere
Described ibuprofen arginine codeine compound sustained release capsules can prepare as follows:
(1) according to above-mentioned fast release micropill recipe quantity, celphere is put in the fluid bed, celphere is suspended by hot-air, ibuprofen arginine, codeine phosphate (are contained PVP, solvent is 50% ethanol) press recipe quantity and mix after, be sprayed onto on the celphere dryly, make required fast release micropill;
(2) according to the slow-release micro-pill recipe quantity, celphere is put in the fluid bed, celphere is suspended, ibuprofen arginine and codeine phosphate solution (are contained PVP by hot-air, solvent is 50% ethanol) be sprayed onto drying on the celphere according to above-mentioned recipe quantity, make slow release ball ball core.Reuse ethyl cellulose, phthalic acid diethanol, talcous acetone/isopropanol liquid mix the back slow release ball core are carried out spray coating, drying, get final product slow-release micro-pill;
(3) slow-release micro-pill and fast release micropill are mixed, the cover capsule can obtain described ibuprofen arginine codeine compound sustained release capsules.
The beneficial effect of Codeine Ibuprofen Arginine Compound Preparation of the present invention is mainly reflected in: (1) ibuprofen has improved the water solublity of ibuprofen because of arginic combination, has improved the human absorptivity; (2) rapid-action, the efficacy stability of preparation and lasting.
(4) specific embodiment
Embodiment 1: preparation ibuprofen arginine codeine compound tablet
Prescription (per 1000 meters):
Ibuprofen arginine 370g
Codeine phosphate 12.5g
Lactose 37.5g
Starch 37.5g
Microcrystalline Cellulose 15g
2% polyvidone aqueous solution 25ml
Pulvis Talci 2.8g
Magnesium stearate 0.9g
Technology:
(1) former, adjuvant are crossed 80 mesh sieves respectively;
(2) get ibuprofen arginine and codeine phosphate recipe quantity and starch mixing, add lactose, microcrystalline Cellulose mixing again;
(3) add 2% polyvidone aqueous solution and make soft material, granulate, 70 ℃ of dryings add Pulvis Talci, magnesium stearate mix homogeneously, tabletting behind the 16 order granulate.
Embodiment 2: preparation ibuprofen arginine codeine compound capsule
Prescription (per 1000 meters):
Ibuprofen arginine 570g
Codeine phosphate 12.5g
Cellulose ethyl hydroxypropyl ether 10g
Starch 5g
Micropowder silica gel 5g
Technology:
(1) 40 mesh sieves, mix homogeneously are crossed in ibuprofen arginine and codeine phosphate, Cellulose ethyl hydroxypropyl ether, starch, the micropowder silica gel of handling recipe quantity respectively;
(2) encapsulated.
Embodiment 3: the compound sustained-released tablet of preparation ibuprofen arginine codeine
Prescription (per 1000 meters)
The slow release label:
Ibuprofen arginine 400g
Lactose 30g
HPMC 60g
(hydroxypropyl emthylcellulose)
Ethyl cellulose 20g
Magnesium stearate 8.2g
Release layer:
Ibuprofen arginine 500g
Codeine phosphate 12.5g
Dyed layer:
Opadry (Opadry) 45g
Technology:
(1) by above-mentioned prescription, the ethanol with 75% is wetting agent, and slow releasing tablet core component ibuprofen arginine, lactose, HPMC, ethyl cellulose are made granule after according to the recipe quantity mix homogeneously, and the adding magnesium stearate is a lubricant, and tabletting obtains the slow release label;
(2) by ibuprofen arginine, codeine phosphate and the 50% pure mix homogeneously of release layer prescription amount, in coating pan, label is carried out coating, make plain sheet;
(3) with above plain sheet further with recipe quantity the Opadry coating, promptly get the compound sustained-released tablet of described ibuprofen arginine codeine.
Embodiment 4: preparation ibuprofen arginine codeine compound sustained release capsules
1) preparation of fast release micropill
Prescription (per 1000 meters):
Ibuprofen arginine 500g
Codeine phosphate 12.5g
2% polyvidone aqueous solution (PVP) 8g
Ethanol 100ml
Celphere 65g
Technology:
According to above-mentioned recipe quantity, celphere is put in the fluid bed, by hot-air celphere is suspended, with ibuprofen arginine, codeine phosphate solution (containing PVP, 50% alcohol solvent 200ml), be sprayed onto drying on the celphere, make described fast release micropill.
2) preparation of slow-release micro-pill
Prescription (per 1000 meters):
Ibuprofen arginine 500g
Codeine phosphate 12.5g
2% polyvidone aqueous solution 15g
Ethanol 150ml
Celphere 180g
Technology:
Celphere is put in the fluid bed, celphere is suspended, ibuprofen arginine and codeine phosphate solution (containing PVP, 50% alcohol solvent 300ml) are sprayed onto drying on the celphere according to above-mentioned recipe quantity, make required slow release ball ball core by hot-air.Reuse ethyl cellulose, phthalic acid diethanol, talcous acetone/isopropanol liquid mix the back slow release ball core are carried out spray coating, drying, get final product slow-release micro-pill;
3) slow-release micro-pill and No. 0 capsule of fast release micropill mixing capsule can be obtained ibuprofen arginine codeine compound sustained release capsules.
Embodiment 5: preparation stability is investigated
Embodiment 1 gained tablet is carried out illumination, hot test and accelerated test, investigate its stability.
1) exposure experiments to light
Get embodiment 1 gained tablet, under light intensity 4000Lx, shine, place sample thief observation mensuration after 0,5,10 day respectively, the results are shown in Table 1.
Table 1. ibuprofen arginine codeine tablet exposure experiments to light result
| Related substance (%) | 0.19 | 0.25 | 0.19 |
| Dissolution (%) | 97 | 97 | 100 |
| Indicate content (%) | 96.9 | 95.6 | 97.8 |
The result shows that this product every index under illumination condition is basicly stable.
2) hot test
Embodiment 1 gained tablet is placed in 60 ℃ of electrothermostats, places sampling observation and mensuration after 5,10 days respectively, result and comparison in 0 day see Table 2.
Table 2. ibuprofen arginine codeine tablet hot test result
The result shows: this product related substance under 60 ℃ of hot conditionss slightly increases, but all less than 1.0%, all the other indexs are basicly stable.
3) accelerated test
Getting embodiment 1 gained tablet, is 40 ℃ ± 2 ℃ in temperature, and relative humidity is to carry out accelerated test under 75% ± 5% condition, the results are shown in Table 3.
Table 3. ibuprofen arginine codeine tablet accelerated test result
| January | 000818 | White tablets | 0.12 | 103 | 99.2 |
| 000821 | White tablets | 0.13 | 102 | 103.5 | |
| 000822 | White tablets | 0.15 | 107 | 102.1 | |
| February | 000818 | White tablets | 0.14 | 102 | 101.8 |
| 000821 | White tablets | 0.15 | 104 | 102.5 | |
| 000822 | White tablets | 0.15 | 109 | 103.5 | |
| March | 000818 | White tablets | 0.13 | 105 | 101.6 |
| 000821 | White tablets | 0.13 | 102 | 103.0 | |
| 000822 | White tablets | 0.12 | 111 | 102.8 | |
| June | 000818 | White tablets | 0.30 | 104 | 100.8 |
| 000821 | White tablets | 0.29 | 105 | 100.7 | |
| 000822 | White tablets | 0.39 | 102 | 102.8 |
The result shows, this product is quickened to investigate six months, every index and relatively having no significant change in 0 month.Can be obtained by above test, ibuprofen arginine codeine tablet stability is good.
Embodiment 6: the antiinflammatory test
Get body weight 140～160g rat, male and female half and half, random packet, 8 every group.Negative control group (normal saline 25ml/kg), positive controls (ibuprofen codeine 34.5mg/kg, wherein contain ibuprofen 32.7mg, codeine contains 1.8mg), embodiment 1 is prepared into the ibuprofen arginine codeine respectively by low dose group (5.4mg/kg), middle dosage group (54mg/kg), high dose group (270mg/kg).By the above-mentioned dosage gastric infusion (ig) of respectively organizing, behind the 1h, the sterile working, injection causes scorching thing (1% carrageenin 0.1ml) under every sufficient plantar aponeurosis in a rat left side.Cause scorching back 1h, 3h measures left and right sides ankle joint girth with special moccasin chi.With the difference of left and right sides ankle joint girth as the swelling degree, contrast between organizing, the poor opposite sex).The results are shown in Table 4.
Table 4. ibuprofen arginine codeine on Carrageenan causes scorching antiinflammatory action
| Group | Dosage (mg/kg) | Number of animals (only) | Swelling degree (mm) r ± s | The P value | ||
| Cause scorching back 1h | Cause scorching back 3h | Compare with saline | Compare with the ibuprofen codeine | |||
| Normal saline | 8 | 6.00±1.25 | 6.81±0.90 | |||
| The ibuprofen codeine | 34.5 | 8 | 2.75±0.65 | 2.72±0.92 | ＜0.01 | |
| The ibuprofen arginine codeine | 5.4 | 8 | 3.18±1.16 | 2.50±0.59 | ＜0.01 | ＞0.05 |
| 54 | 8 | 1.50±1.20 | 2.52±0.62 | ＜0.01 | ＞0.05 | |
| 270 | 8 | 1.23±0.82 | 1.20±0.67 | ＜0.01 | ＜0.05 | |
By last table result as can be seen: during high dose group, effect obviously is better than the ibuprofen codeine to the antiinflammatory action of ibuprofen arginine codeine about 1h and in giving.
Embodiment 7: the analgesic test
Get 60 of body weight 17～22g mices, male and female half and half, random packet, 12 every group.If the group situation reaches and respectively organizes gastric infusion dosage with embodiment 6.Ip0.6% acetic acid behind the 30min (0.2ml/ only) causes pain, raises to causing indicator reaction bitterly with mouse writhing (abdominal part caves in, trunk uphold with hind leg) buttocks.Turn round the body number of times behind the self-supporting acetic acid of observed and recorded in the 15min.The results are shown in Table 5.
Table 5. ibuprofen arginine codeine is to the analgesic activity of mice
| Group | Dosage (mg/kg) | Number of animals (only) | Swelling degree (g) x ± S | The P value | |
| Compare with saline | Compare with the ibuprofen codeine | ||||
| Normal saline | 12 | 20.60±5.23 | |||
| The ibuprofen codeine | 34.5 | 12 | 5.76±1.52 | ＜0.05 | |
| The ibuprofen arginine codeine | 5.4 | 12 | 6.23±2.30 | ＜0.01 | ＞0.05 |
| 54 | 12 | 5.12±2.19 | ＜0.01 | ＞0.05 | |
| 270 | 12 | 2.85±0.47 | ＜0.01 | ＜0.05 | |
By last table result as can be seen: ibuprofen arginine codeine compound tablet is when middle dosage, and its analgesic activity is suitable with the ibuprofen codeine, and when giving high dose, analgesic activity obviously is better than the ibuprofen codeine.
Embodiment 8: separate heat test
Get 40 of body weight 1.6～2.0kg rabbit, male and female half and half, random packet, 8 every group.The ibuprofen arginine codeine tablet of negative control group (normal saline 1ml/kg), positive controls (ibuprofen codeine 17.5mg/kg), embodiment 1 preparation is by low dose group (3.5mg/kg), middle dosage group (16.8mg/kg), high dose group (78.5mg/kg).After measuring the rabbit normal body temperature, injection colibacillus deactivating liquid (about 1012/kg antibacterial, reduced turbidity calculates) pyrogenicity.Take temperature is as the fever index behind 3～4h.Reduce number as separating heating index with each time point body temperature behind the gastric infusion.Compare with the body temperature before the back administration that heats up, the results are shown in Table 6.
Table 6 ibuprofen arginine codeine is to the influence of rabbit body temperature
| Group | Dosage (mg/kg) | Give behind the bacterium before the administration elevated temperature ℃ | Different time body temperature reduction value after the administration (℃) x ± S | |||
| 60min | 90min | 120min | 150min | |||
| Normal saline | 1.53±0.13 | 0.11±0.10 | 0.15±0.10 | 0.075±0.10 | 0.35±0.20 | |
| The ibuprofen codeine | 17.5 | 1.23±0.07 | 0.13±0.10 | 0.61±0.10 | 0.92±0.10 | 1.03±0.20 |
| The ibuprofen arginine codeine | 3.5 | 1.55±0.18 | 0.26±0.10 | 0.47±0.20 | 0.80±0.20 | 0.89±0.20 |
| 16.8 | 1.29±0.08 | 0.72±0.10 | 0.84±0.20 | 0.99±0.10 | 1.09±0.20 | |
| 78.5 | 1.69±0.14 | 0.92±0.10 | 1.08±0.20 | 1.25±0.29 | 1.39±0.10 | |
By last table result as can be seen: in giving ibuprofen arginine codeine compound tablet during dosage, its for the body-temp. reducing effect of rabbit obviously faster than the ibuprofen codeine.But the body-temp. reducing effect basically identical after two hours.
Claims (1)
1, the compound sustained-released tablet of a kind of ibuprofen arginine codeine is characterized in that described slow releasing tablet is made up of slow release label, release layer and dyed layer:
Described slow releasing tablet core component and quality proportioning are:
240～600 parts of ibuprofen arginines
30 parts of lactose
60 parts of HPMC
20 parts of ethyl celluloses
8.2 parts of magnesium stearate
Described release layer component and quality proportioning are:
500 parts of ibuprofen arginines
12.5 parts of codeine phosphates
Described dyed layer is 45 parts of Opadries
Described slow releasing tablet prepares as follows:
A, by above-mentioned prescription, the ethanol with 75% is wetting agent, and slow releasing tablet core component ibuprofen arginine, lactose, HPMC, ethyl cellulose are made granule after according to the recipe quantity mix homogeneously, the adding magnesium stearate is a lubricant, tabletting obtains the slow release label;
B, will in coating pan, carry out coating, make plain sheet by ibuprofen arginine, codeine phosphate and the 50% ethanol mix homogeneously of release layer group component to label;
C, with above plain sheet further with the Opadry coating of recipe quantity, promptly get the compound sustained-released tablet of described ibuprofen arginine codeine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016416 CN1273137C (en) | 2004-02-16 | 2004-02-16 | Compound prepn. contg. Brufen arginine codeine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410016416 CN1273137C (en) | 2004-02-16 | 2004-02-16 | Compound prepn. contg. Brufen arginine codeine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559409A CN1559409A (en) | 2005-01-05 |
| CN1273137C true CN1273137C (en) | 2006-09-06 |
Family
ID=34440462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410016416 Expired - Fee Related CN1273137C (en) | 2004-02-16 | 2004-02-16 | Compound prepn. contg. Brufen arginine codeine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1273137C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940144A (en) * | 2015-05-28 | 2015-09-30 | 华润三九医药股份有限公司 | Ibuprofen slow-release pellets and preparation method thereof |
-
2004
- 2004-02-16 CN CN 200410016416 patent/CN1273137C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1559409A (en) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1762357A (en) | Oral medicinal formulation of moxifloxacin and its preparation method | |
| CN1296052C (en) | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate | |
| CN1799543A (en) | Telmisartan dispersible tablet and its preparation method | |
| CN1839814A (en) | Methionine enteric casing preparation and its preparing process | |
| CN1872279A (en) | Composition of medication for treating ulcer in the oral cavity, and preparation method | |
| CN1273137C (en) | Compound prepn. contg. Brufen arginine codeine | |
| CN1562018A (en) | Cilostazol solid dispersion and its method for preparing tablet | |
| CN1268327C (en) | Brufen arginine pseudoephedrine hydrochloride compound formulation | |
| CN1915216A (en) | New usage of tandospirone and its derivative, and composition containing tandospirone | |
| CN1634087A (en) | Sustained release formulation of glucosamine salt, its preparation and usage | |
| CN101028518A (en) | Medicinal composition containing silver ester medicine and ibobulodine | |
| CN1301108C (en) | Metaducine dispersion tablet and its preparation method | |
| CN100336511C (en) | Release-controlled oral Roxithromycin formulation | |
| CN1680390A (en) | Halogenated dihydroartemisine, preparation and use thereof | |
| CN1303990C (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN1500487A (en) | Oral compound levocetirizine pseudoephedrine formulation and its preparation | |
| CN1810242A (en) | Slow-released vincamine capsule and its prepn process | |
| CN1891265A (en) | Ginseng-aconite orally disintegrating tablet and its preparing method | |
| CN1217655C (en) | Fibrauretine slow releasing prepn | |
| CN101066252A (en) | Aminoglucose calcium tablet and its prepn process | |
| CN1682723A (en) | Scopolamine hydrobromide dry powder inhalant for nose and preparing method | |
| CN1429618A (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method | |
| CN1875950A (en) | Compound capsule of glycyrrhzin and preparation method thereof | |
| CN1277544C (en) | Composite analgesic composition and its use | |
| CN1296045C (en) | Oral disintegration tablet of dihydroergotoxine and its derivatives and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CHINA PHARMACY UNIVERSITY Free format text: FORMER OWNER: RONGLI MEDICINE SCI. + TECH. CO., LTD., HANGZHOU Effective date: 20060224 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20060224 Address after: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Applicant after: China Pharmaceutical University Address before: 310012, building 1, building 2, Huaxing Industrial Village, No. 18 Miao Miao Road, Zhejiang, Hangzhou Applicant before: Hangzhou Rongli Medicine Science &. Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Chengong Pharmaceuticals Co., Ltd., Nanjing Assignor: China Pharmaceutical University Contract fulfillment period: 2006.8.25 to 2011.10.1 contract change Contract record no.: 2008320000283 Denomination of invention: Compound prepn. contg. Brufen arginine codeine Granted publication date: 20060906 License type: Exclusive license Record date: 2008.9.23 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.8.25 TO 2011.10.1 Name of requester: NANJING CHEN GONG PHARMACEUTICAL CO., LTD. Effective date: 20080923 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060906 Termination date: 20170216 |